The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1016
December 19, 1997
View Complete Issue         Table of Contents 2019 
Anagrelide for Essential Thrombocythemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Anagrelide for Essential Thrombocythemia
December 19, 1997 (Issue: 1016)
Anagrelide (an ag' gre lide) hydrochloride (Agrylin - Roberts), a quinazolin derivative, has been approved by the FDA for oral treatment of essential thrombocythemia. Patients with this uncommon myeloproliferative disorder have an increased number...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Anagrelide for Essential Thrombocythemia
Article code: 1016c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.